This webinar highlights the need to evolve to more flexible and modular facility designs that can be built in a factory, shipped to the site and then rapidly assembled how it is being addressed by innovative suppliers in different ways.
Address optimal configuration of a multi-column continuous chromatography (MCC) system, with insight into the impact antibody titer has on the number of chromatography columns required to optimize productivity of a MCC process.
Examine common regulatory challenges and areas of uncertainty in the implementation of continuous bioprocessing, and understand practical, total solutions.
Review simplified continuous filtration, particularly for UF/DF, with a look into our exclusive license to patents in the field of single-pass tangential flow filtration (SPTFF), which enables continuous filtration without recirculation at several stages of a continuous bioprocess.
Addressing the concerns regarding limiting the rapid adoption and implementation of single-use technology has centered on standardizing single-use component extractables data packages to be used for end user risk assessments.
Discover how you enhance the removal of HCPs and aggregates during mAbs production with versatile solutions that deliver over a broad range of conductivity and pH to fit with any mAb, while using a platform process adaptable to both batch and continuous processing.
As compared to IV route, ODT can provide a convenient oral route of administration for proteins, peptides and vaccines. Join experts from Catalent for an overview of the challenges and opportunities in using ODT technology as a patient-centric drug delivery tool and get updates on the new developments in ODT technology including delivery of peptides and vaccines.
This webinar highlights the advantages when working with one source on your mAb, linker/payload supplies, and conjugation services.
With transformational changes in biologics, there are increasingly newer formats of new biologic drugs including bispecific antibodies, antibody drug conjugates and antibody-peptide fusion proteins.
The complex structure of Biologics, the nature of the interactions with their partners, require accurate modelling method to predict their physicochemical properties.
|
|
|
|
|
|
|
|
|